CURRENT MEMBERS

Postdoctoral researchers

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Doctoral researchers

The role of connexins, pannexins and their channels in cholestasis

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Alanah Pieters

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Bruna dos Santos Rodrigues

Development and testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. M. Sci. Andrés Tabernilla

The role of connexins, pannexins and their channels in cholestasis

To be defended in 2022

Promoters: Mathieu Vinken, Pieter Annaert

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be defended in 2022

Promoters: Mathieu Vinken, Lindsey Devisscher

Co-promoter: Tamara Vanhaecke

Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study

To be defended in 2022

Promoters: Mathieu Vinken, Tamara Vanhaecke

The role of connexins, pannexins and their channels in liver cancer

To be defended in 2022

Promoter: Mathieu Vinken

Co-promoter: Bruno Cogliati

Development of nanobody-based inhibitors of connexin hemichannels and pannexin channels as novel therapeutics for the treatment of liver disease

To be defended in 2022

Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans

Development and in vitro testing of peptidomimetic-based inhibitors of pannexin1 channels

To be defended in 2023

Promoters: Mathieu Vinken, Steven Ballet

​

Scientific collaborators

Development of nanobody-based inhibitors of connexin43 hemichannels

To be completed in 2021

Promoter: Mathieu Vinken

M. Sci. Ana Rita Coelho Gomes

Technicians

Dinja De Win

FORMER TEAM MEMBERS

Dr. M. Sci. Sara Crespo-Yanguas

Dr. Pharm. Michaël Maes

Dr. Pharm. Joost Willebrords

Miss Tineke Vanhalewyn

FINISHED POSTDOCTORAL PROJECTS

Role of connexin and pannexin (hemi)channels in liver cancer

Tereza Cristina da Silva: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

​

Role of connexin and pannexin (hemi)channels in hepatitis

Isabel Veloso Alves Pereira: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

​

Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury

Vânia Vilas-Boas: completed 31/12/2020

Promoter: Mathieu Vinken

FINISHED DOCTORAL PROJECTS

Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures

Tatyana Doktorova: defended 16/03/2012

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes

Eva Ramboer: defended 15/10/2015

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

The role of connexins, pannexins and their channels in acute liver failure

Michaël Maes: defended 17/10/2017

Promoters: Mathieu Vinken, Bruno Cogliati

The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis

Joost Willebrords: defended 29/01/2018

Promoters: Mathieu Vinken, Bruno Cogliati

The role of connexins, pannexins and their channels in liver fibrosis

Sara Crespo Yanguas: defended 25/10/2018

Promoters: Mathieu Vinken, Bruno Cogliati

Connexin43 hemichannels as druggable targets for future anti-seizure medication

Laura Walrave: defended 24/01/2019

Promoter: Ilse Smolders

Co-promoters: Mathieu Vinken, Luc Leybaert

© 2023 by InVitroTox Consulting.

Proudly created using Wix.com